NCT06793943View on ClinicalTrials.gov

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 23, 2025

Primary Completion Date

March 11, 2025

Study Completion Date

March 30, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

Zasocitinib

Zasocitinib tablets specified doses on specified days.

DRUG

COC

COC tablets (containing LNG and EE) specified doses on specified days.

DRUG

Metformin

Metformin tablets specified doses on specified days.

DRUG

Digoxin

Digoxin tablets specified doses on specified days.

DRUG

Esomeprazole

Esomeprazole capsules specified doses on specified days.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT06793943 - A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults | Biotech Hunter | Biotech Hunter